Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Final Trade: F, HAL, MA, GILD
06:21pm, Tuesday, 21'st Oct 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
06:30am, Tuesday, 21'st Oct 2025
WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
Medical Stocks Worth Watching – October 18th
01:40am, Monday, 20'th Oct 2025
Hims and Hers Health, Eli Lilly and Company, UnitedHealth Group, Gilead Sciences, AbbVie, Johnson and Johnson, and Thermo Fisher Scientific are the seven Medical stocks to watch today, according to Ma
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
08:30am, Sunday, 19'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlan
Gilead's Trodelvy cuts breast cancer risk by 38% in trial
02:33am, Sunday, 19'th Oct 2025
Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically m
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
10:00pm, Saturday, 18'th Oct 2025
Gilead Sciences (GILD) is a top-performing healthcare stock in 2025, up 36% YTD and breaking out to all-time highs. GILD's strong Q2 results, raised guidance, and robust HIV portfolio drive optimism,
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 16'th Oct 2025
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
03:30am, Wednesday, 15'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from Octob
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
10:33am, Monday, 13'th Oct 2025
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
08:30am, Monday, 13'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at t
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
10:11pm, Friday, 10'th Oct 2025
Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an addi
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
01:44pm, Friday, 10'th Oct 2025
The Investment Committee give you their top stocks to watch for the second half.
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
04:05pm, Thursday, 09'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Wednesday, 08'th Oct 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
